((自动化翻译由路透提供，请见免责声明 ))
9月12日 - ** 癌症疗法开发商Oncternal Therapeutics 股价创新低，最后下跌59.32%，报1.69美元
** 该公司表示将停止 (link) 其实验性癌症疗法 ONCT-534 和 ONCT-808 的试验，并将探索战略替代方案
** 在早期试验中，ONCT-534（对转移性阉割耐药癌症患者进行的研究）没有显示出有临床意义的病情改善。
** 在 ONCT-808 试验的最高剂量下，有一人因休克并发症死亡
** 虽然战略探索仍在进行，但公司将停止所有产品开发活动，并将采取其他措施降低成本，包括裁员以保留现金资源
** 股价在过去一年中下跌了 85
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.